Sientra, Inc.

Sientra, Inc.

SIEN

SIENSientra, Inc. US flag

NASDAQ Global Select

0.17

USD

-0.04

- -

2.08MMarket Cap

Sientra, Inc.

SIEN

(NASDAQ Global Select)

Recent

price

0.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Lombard Medical, Inc. (EVARF)
Bioptik Technology Incorporation (4161.TWO)
Rafina Innovations Inc. (VICA)
NanoVibronix, Inc. (NAOV)
Inari Medical, Inc. (NARI)
Ikonisys S.A. (ALIKO.PA)
Business: Sientra, Inc. is a medical aesthetics company primarily engaged in the development, manufacturing, and commercialization of breast implants and related products used in breast augmentation and reconstruction surgeries. The company's product portfolio includes FDA-approved fifth-generation round and shaped silicone gel breast implants; the AlloX2® and AlloX2Pro™ breast tissue expanders featuring patented dual-port and integral drain technology; the Viality™ fat transfer system enhanced with AuraClens™ for high viability fat transfer; the SimpliDerm human acellular dermal matrix for reconstructive procedures; and BIOCORNEUM®, a leading scar management silicone gel product. Founded in 2007 and headquartered in Santa Barbara, California, Sientra markets its products primarily to board-certified plastic surgeons and operates within the United States. In recent major developments, Sientra filed for Chapter 11 bankruptcy protection in February 2024 and has since pursued the sale of key business assets. In April 2024, Tiger Aesthetics Medical, LLC acquired substantially all assets related to Sientra’s breast implant and tissue expander business, including the manufacturing facilities in Franklin, Wisconsin, and assumed certain liabilities and customer warranties. Concurrently, Nuance Intermediary, LLC acquired the assets of Sientra's BIOCORNEUM scar management business in an $8 million cash transaction. Under the new ownership of Tiger Aesthetics, a company specializing in regenerative medicine and aesthetic products, the Sientra brand continues to offer its established portfolio while planning to expand into innovative regenerative aesthetic therapies, leveraging Sientra's market presence and advanced technologies. These strategic asset sales signify a major operational and ownership restructure aimed at financial stability and long-term growth within the aesthetics market segment. Tiger Aesthetics has committed to maintaining existing manufacturing and operational standards as part of the integration process. Sientra’s offerings now align with regenerative medicine initiatives and aesthetic device innovation under the Tiger Aesthetics umbrella. These changes mark a significant shift from the company's prior independent operations to being a division within a broader regenerative medical aesthetics platform.

Company News